Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...
With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...
EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Shares of Vertex Pharmaceuticals Inc. VRTX slipped 3.14% to $455.22 Tuesday, on what proved to be an all-around favorable ...
Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback